drugset
Drugs / CAMIBIRSTAT
last change Sep 2026 re-read 9 days ago

CAMIBIRSTAT

also known as FHD-286

Small molecule targets SMARCA2, SMARCA4 via inhibition

Developed for
acute myeloid leukemia · myelodysplastic syndrome · chronic myelomonocytic leukemia · small cell lung carcinoma · uveal melanoma
Investigated by
Foghorn Therapeutics Inc. · Dana-Farber Cancer Institute · Montefiore Medical Center

Trials 4

today NCT07551635 · Ph 2 NCT07283094 · Ph 1 NCT04891757 · Ph 1 NCT04879017 · Ph 1
2022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT07283094 Feb 2026 → May 2028 expected acute myeloid leukemia, myelodysplastic syndrome Montefiore Medical Center Recruiting No outcome recorded
Phase 1 NCT04891757 Jun 2021 → Sep 2025 overdue acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome Foghorn Therapeutics Inc. Active not recruiting No outcome recorded
Phase 1 NCT04879017 May 2021 → Nov 2023 uveal melanoma Foghorn Therapeutics Inc. Terminated No outcome recorded Stop: Business
Phase 21 trial
Phase 2 NCT07551635 Sep 2026 → Jan 2028 expected small cell lung carcinoma Dana-Farber Cancer Institute Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 7

DateIssuerRelease
2024-12-16 Foghorn Therapeutics Inc. Results Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities foghorntx.com ↗
In the Phase 1 dose escalation trial of FHD-286 in combination with decitabine in relapsed and/or refractory AML, objective clinical responses were observed by standard response criteria.
2023-06-28 Foghorn Therapeutics Inc. Results Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma foghorntx.com ↗
In the study, nine patients had stable disease and one patient had a durable partial response
2023-06-05 Foghorn Therapeutics Inc. Regulatory Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients foghorntx.com ↗
2022-11-09 Foghorn Therapeutics Inc. Results Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting foghorntx.com ↗
The poster will highlight new data demonstrating the potential of FHD-286, in combination with an anti-PD-1 antibody, to provide synergistic efficacy and survival benefit compared to anti-PD-1 alone in preclinical models.
2022-08-23 Foghorn Therapeutics Inc. Regulatory Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS foghorntx.com ↗
2022-05-19 Foghorn Therapeutics Inc. Regulatory Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS foghorntx.com ↗
2022-04-13 Foghorn Therapeutics Inc. Results Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting foghorntx.com ↗

All press releases naming this drug 14 releases

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as CAMIBIRSTAT ChEMBL registry synonym — accepted as the source's own label CHEMBL5095181 ↗
Known as FHD-286 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07551635 ↗
3

NCT04879017 ↗

NCT07283094 ↗

NCT04891757 ↗
Action Inhibit “FHD-286, a dual BRG1/BRM (Brahma related gene 1/Brahma homolog) inhibitor” PMID 40238563 ↗ Jun 2025
Modality Small molecule “a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor” NCT07551635 ↗
Route Oral “when administered orally to subjects” NCT04879017 ↗
Target SMARCA2 “FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor” PMID 40238563 ↗ Jun 2025